Family and Adolescent Motivational Incentives for Leveraging Youth (FAMILY)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01736995 |
Recruitment Status :
Completed
First Posted : November 29, 2012
Last Update Posted : May 2, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Substance-Related Disorders | Behavioral: Functional Family Therapy Behavioral: Motivational Enhancement Tx/Cognitive Behavioral Tx Behavioral: Contingency Management | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 212 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Family and Adolescent Motivational Incentives for Leveraging Youth |
Actual Study Start Date : | July 2012 |
Actual Primary Completion Date : | April 2018 |
Actual Study Completion Date : | April 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Motivational/Cog Beh Tx-Contingency Mgmt
The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
|
Behavioral: Contingency Management
Other Name: CM |
Experimental: Functional Family Tx- Contingency Mgmt
Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers to the family as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
|
Behavioral: Functional Family Therapy
Other Name: FFT Behavioral: Contingency Management Other Name: CM |
Experimental: Motivational/Cog Beh Tx
The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention.
|
Behavioral: Motivational Enhancement Tx/Cognitive Behavioral Tx
Other Name: MET/CBT |
Experimental: Functional Family Tx
Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills.
|
Behavioral: Functional Family Therapy
Other Name: FFT |
- Urine Assays - NIDA 12 Test Panel [ Time Frame: Up to 12-months after randomization ]The NIDA 12 Test Panel is a card device with 12 finger-like prongs, dipped in a urine sample to screen for the presence or absence of illegal substances including AMP (amphetamine), BAR (barbiturates), BZO (benzodiazepines), COC (cocaine), M-AMP/MDMA (methamphetamine, ice, speed, ecstasy), MTD (methadone), MOR (morphine), OXY (Oxycodone), PCP, PPX (Propoxyphene), OPI (Opiates), THC (marijuana). Alcohol use will be measured using Saliva Screens (Alco-Screen 02), a simple, non-invasive, one-step test that provides results in four minutes and detects alcohol levels of .02 or greater.
- Timeline Followback semi-structured interview (TLFB) [ Time Frame: Up to 12-months after randomization ]The TLFB will be used to determine the percent days of substance use (primary measure), excluding tobacco, as well as abstinence days and binge drinking days.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 13 Years to 17 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 13 to 17 years of age
- Meets DSM-IV diagnostic criteria for substance abuse or dependence
- Living at home with the participating parent
- Sufficient residential stability to permit probable contact at follow- up(e.g., not homeless at time of intake)
Exclusion Criteria:
- Evidence of psychotic or organic state of sufficient severity to interfere with the understanding of study instruments and procedures
- Deemed dangerous to self or others at intake
- Services other than outpatient treatment are required for the youth (e.g., inpatient, detoxification)
- Marijuana use is reported as being less than 13% of the previous 90 days

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01736995
United States, New Mexico | |
Oregon Research Institute Center for Family and Adolescent Research | |
Albuquerque, New Mexico, United States, 87102 |
Principal Investigator: | Michael Robbins, Ph.D. | Oregon Research Institute; Functional Family Therapy, Inc. |
Responsible Party: | Oregon Research Institute |
ClinicalTrials.gov Identifier: | NCT01736995 |
Other Study ID Numbers: |
1R01DA032723-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | November 29, 2012 Key Record Dates |
Last Update Posted: | May 2, 2018 |
Last Verified: | May 2018 |
Substance Abuse Adolescents Families Functional Family Therapy |
Cognitive Behavioral Therapy Motivational Therapy Contingency Management |
Substance-Related Disorders Chemically-Induced Disorders Mental Disorders |